CN116249531A - 用于激活丙酮酸激酶的组合物和方法 - Google Patents
用于激活丙酮酸激酶的组合物和方法 Download PDFInfo
- Publication number
- CN116249531A CN116249531A CN202180058558.3A CN202180058558A CN116249531A CN 116249531 A CN116249531 A CN 116249531A CN 202180058558 A CN202180058558 A CN 202180058558A CN 116249531 A CN116249531 A CN 116249531A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- heterocycle
- cycloalkyl
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054478P | 2020-07-21 | 2020-07-21 | |
| US63/054,478 | 2020-07-21 | ||
| PCT/US2021/042489 WO2022020424A1 (en) | 2020-07-21 | 2021-07-21 | Compositions and methods for activating pyruvate kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116249531A true CN116249531A (zh) | 2023-06-09 |
Family
ID=79728915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180058558.3A Pending CN116249531A (zh) | 2020-07-21 | 2021-07-21 | 用于激活丙酮酸激酶的组合物和方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230374017A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185293A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023535027A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249531A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021311597B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183980A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020424A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233063B2 (en) | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
| WO2023052783A1 (en) * | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| CN118434720A (zh) | 2021-12-22 | 2024-08-02 | 西特瑞治疗有限公司 | 作为丙酮酸激酶调节剂的酞嗪衍生物 |
| WO2023211999A1 (en) * | 2022-04-29 | 2023-11-02 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173415A2 (en) * | 2008-10-09 | 2017-05-31 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Activators of human pyruvate kinase |
| WO2019035863A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals, Inc. | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS |
| WO2020167976A1 (en) * | 2019-02-13 | 2020-08-20 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137320A1 (en) * | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| US8563580B2 (en) * | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2968323A4 (en) * | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| US12233063B2 (en) * | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
-
2021
- 2021-07-21 CA CA3183980A patent/CA3183980A1/en active Pending
- 2021-07-21 US US18/017,108 patent/US20230374017A1/en active Pending
- 2021-07-21 AU AU2021311597A patent/AU2021311597B2/en active Active
- 2021-07-21 JP JP2023504298A patent/JP2023535027A/ja active Pending
- 2021-07-21 CN CN202180058558.3A patent/CN116249531A/zh active Pending
- 2021-07-21 WO PCT/US2021/042489 patent/WO2022020424A1/en not_active Ceased
- 2021-07-21 EP EP21846999.7A patent/EP4185293A4/en active Pending
-
2026
- 2026-02-10 JP JP2026020484A patent/JP2026097841A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173415A2 (en) * | 2008-10-09 | 2017-05-31 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Activators of human pyruvate kinase |
| WO2019035863A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals, Inc. | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS |
| WO2020167976A1 (en) * | 2019-02-13 | 2020-08-20 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Non-Patent Citations (1)
| Title |
|---|
| 剧仑等: "吡咯并吡啶类整合酶抑制剂的设计、合成和生物活性研究", 国际药学研究杂志, vol. 43, no. 5, 31 October 2016 (2016-10-31), pages 940 - 946 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183980A1 (en) | 2022-01-27 |
| JP2023535027A (ja) | 2023-08-15 |
| EP4185293A1 (en) | 2023-05-31 |
| AU2021311597B2 (en) | 2026-08-06 |
| US20230374017A1 (en) | 2023-11-23 |
| EP4185293A4 (en) | 2025-01-15 |
| JP2026097841A (ja) | 2026-06-16 |
| WO2022020424A1 (en) | 2022-01-27 |
| AU2021311597A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10858335B2 (en) | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | |
| US10399951B2 (en) | Compounds and compositions for inhibition of FASN | |
| CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| KR101871436B1 (ko) | 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물 | |
| CN116723843A (zh) | 用于治疗和/或预防癌症的sos1抑制剂的药物组合 | |
| CA3142340A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| CN103596926B (zh) | 作为raf激酶抑制剂的稠合三环化合物 | |
| JP2023535027A (ja) | ピルビン酸キナーゼを活性化するための組成物及び方法 | |
| CN102399218A (zh) | 一类并合三杂环及其作为pi3k抑制剂的用途 | |
| WO2018090939A1 (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
| CN103282363B (zh) | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 | |
| JP2011525535A (ja) | PI3K/mTOR阻害剤 | |
| US20250215013A1 (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
| CA3219925A1 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer | |
| JP6953527B2 (ja) | 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用 | |
| JP7648043B2 (ja) | ターピリジンジケトン化合物、またはその塩、ならびにそれらの調製方法および使用 | |
| KR20140014104A (ko) | 치환된 이미다조퀴놀린 유도체 | |
| JP2023528074A (ja) | Gpr65のモジュレーターとしてのn-(フェニルアミノカルボニル)テトラヒドロ-イソキノリン及び関連する化合物 | |
| WO2021244609A1 (zh) | 具有大环结构的化合物及其用途 | |
| JP2024521900A (ja) | メチオニンアデノシルトランスフェラーゼ2a阻害剤 | |
| KR20250073623A (ko) | AhR 신호전달의 조절에 유용한 화합물 | |
| TWI888920B (zh) | 苯基取代的二氫萘啶類化合物及其製備與用途 | |
| CN120699000A (zh) | 一种杂双环类化合物及其制备方法与应用 | |
| CN118420607A (zh) | 杂芳环化合物及其应用 | |
| CN119192175A (zh) | 化合物、药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |